Diabefarm, tablets 80 mg 60 pcs

Pharmacotherapeutic group: oral hypoglycemic agent of generation II sulfonylurea group

ATC code: A10BV09

Pharmacological action

Pharmacodynamics

Glicliquid stimulates insulin secretion by pancreatic p-cells, increases insulin-secretory action of glucose, increases peripheral tissue sensitivity to insulin. Stimulates the activity of intracellular enzymes – muscle glycogen synthetase. Reduces the period of time from the moment of food intake to the beginning of insulin secretion. Restores the early peak of insulin secretion (unlike other sulfonylurea derivatives, which have an effect mainly during the second stage of secretion).

Limits postprandial increase of blood glucose level.
Besides influence on carbohydrate metabolism it improves microcirculation: decreases adhesion and aggregation of thrombocytes, normalizes vascular permeability, prevents development of microthrombosis and atherosclerosis, restores process of physiological fasting fibrinolysis. It reduces the sensitivity of vascular receptors to adrenaline.

It slows down the development of diabetic retinopathy at the iaproliferative stage. In diabetic nephropathy against the background of long-term use there is a significant reduction in the severity of proteinuria. It does not lead to weight gain, as it mainly influences the early peak of insulin secretion and does not cause hyperinsulinemia; it promotes weight loss in obese patients by keeping a proper diet. Has anti-atherogenic properties, lowers the blood concentration of total cholesterol.

Pharmacokinetics

After oral administration is quickly absorbed in the gastrointestinal tract. Absorption is high. After oral administration of 80 mg, maximum concentration in blood (2.2-8 mcg/ml) is reached after about 4 hours, after administration of 40 mg, maximum concentration in blood (2-3 mcg/ml) is reached after 2 -3 hours. Plasma protein binding is 85-97%, the volume of distribution is 0.35 l/kg. Equilibrium concentration in blood is reached after 2 days. It is metabolized in liver, 8 metabolites are formed.

The amount of the main metabolite found in the blood is 2-3 % of the total amount of the drug taken, it has no hypoglycemic effect, but improves microcirculation. It is excreted by the kidneys – 70% as metabolites, less than 1% unchanged; through the intestines – 12% as metabolites.
Half-life is 8 – 20 hours.

Indications

Active ingredient

Composition

How to take, the dosage

Interaction

Special Instructions

Contraindications

Hypersensitivity to the drug; type 1 diabetes mellitus; diabetic ketoacidosis, diabetic precoma, diabetic coma; hyperosmolar coma; severe hepatic and/or renal failure; major surgical interventions, extensive burns, injuries and other conditions requiring insulin therapy; intestinal obstruction, paresis of the stomach; conditions accompanied by disorders of food absorption, the development of hypoglycemia (infectious diseases); leukopenia; pregnancy, breast-feeding, children under 18 years of age.

With caution (need for closer monitoring and dose selection) is administered in febrile syndrome, alcoholism and thyroid disease (with impaired thyroid function).

Side effects

Overdose

Pregnancy use

Similarities